Similar to the S. aureus skin infection, TNFR2 agonist–treated mice had substantially decreased skin lesion sizes (Fig. 8, A and B) and reduced bacterial burden compared to vehicle-treated mice (Fig. 8, C and D). This evidence concerns the gene TNFRSF1B and skin infection.